Clinical Trial

A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a prospective phase II clinical trial aimed at exploring the potential benefits of supplementing β-hydroxybutyrate with existing short course radiotherapy sequential immunotherapy and CAPEOX therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-15.
Status change: Not Yet Recruiting → Recruiting 2026-04-20
Trial Details
NCT Number NCT07239466
Lead Sponsor Tao Zhang
Conditions Rectal Cancer, Radiotherapy, Immunotherapy, Chemotherapy
Enrollment 25 participants
Start Date 2026-01-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-23